|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115166 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-23 14:15:32 |
|
注册时间: Date of Registration: |
2025-12-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
增强现实技术(AR)联合五行音乐疗法对于改善乳腺微创手术患者焦虑症状的临床研究:一项单中心、随机对照、单盲、开放标签的临床试验 |
|
Public title: |
Clinical study on the combination of Augmented Reality (AR) technology and Five-Element Music Therapy for Improving Anxiety Symptoms in Patients undergoing Minimally invasive Breast Surgery: A single-center, randomized controlled, single-blind, open-label clinical trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于虚拟现实技术的乳腺局麻手术术前术中健康教育系统的构建和应用研究 |
|
Scientific title: |
Construction and Application Study of a Virtual Reality-Based Preoperative and Intraoperative Health Education System for Breast Surgery under Local Anesthesia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴小珍 |
研究负责人: |
吴小珍 |
|
Applicant: |
Wu Xiaozhen |
Study leader: |
Wu Xiaozhen |
|
申请注册联系人电话: Applicant telephone: |
+86 137 6079 3982 |
研究负责人电话: Study leader's telephone: |
+86 137 6079 3982 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
287840600@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
287840600@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区人民路402号 |
研究负责人通讯地址: |
广东省广州市越秀区人民路402号 |
|
Applicant address: |
402 Renmin Road, Yuexiu District, Guangzhou City, Guangdong Province, China |
Study leader's address: |
402 Renmin Road, Yuexiu District, Guangzhou City, Guangdong Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州医科大学附属妇女儿童医疗中心 |
||
|
Applicant's institution: |
Guangzhou Women and Children's Medical Center |
||
|
研究负责人所在单位: |
广州医科大学附属妇女儿童医疗中心 |
||
|
Affiliation of the Leader: |
Guangzhou Women and Children's Medical Center |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
穗妇儿 科伦 批字[2025]第394A01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属妇女儿童医疗中心科研伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee, Guangzhou Medical University Affiliated Women and Children's Medical Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-05 00:00:00 |
||
|
伦理委员会联系人: |
斯文越 |
||
|
Contact Name of the ethic committee: |
Si Wenyue |
||
|
伦理委员会联系地址: |
广东省广州市天河区金穗路9号 |
||
|
Contact Address of the ethic committee: |
9 Jinsui Road, Tianhe District, Guangzhou City, Guangdong Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 3836 7837 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属妇女儿童医疗中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Guangzhou Women and Children Medical Center, Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区人民路402号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
402 Renmin Road, Yuexiu District, Guangzhou City, Guangdong Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
Target disease: |
Breast mass |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
旨在通过VR技术联合五行音乐疗法,缓解乳腺疾病患者微创手术中焦虑状态,改善患者手术的体验,减轻患者的心理负担,评价VR技术联合五行音乐疗法对改善接受乳腺微创手术患者的焦虑状态的临床有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study is to relieve the anxiety state of patients with breast disease during minimally invasive surgery by VR technology combined with five elements music therapy, improve the experience of surgery and reduce the psychological burden of patients, and to evaluate the clinical efficacy and safety of VR technology combined with five elements music therapy in improving the anxiety state of patients undergoing minimally invasive breast surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合乳房良性肿瘤、乳腺纤维囊性增生、乳腺腺病、乳腺纤维囊性乳腺病其中之一的诊断标准; 2.年龄18-70岁(含18周岁和70周岁)的女性; 3.符合超声引导下真空辅助乳腺活检手术(vac uum-assisted breast biopsy,VABB)适应症的患者; 4.术前医院焦虑抑郁量表(HADS)评分显示患者存在焦虑抑郁的患者,即SAS评分≥7分; 5.自愿参加本试验,征得本人即家属同意,并签署知情同意的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria of benign breast tumor, breast fibrocystic hyperplasia, breast adenosis, breast fibrocystic breast disease; 2. Women aged 18-70 years old (including 18 and 70 years old); 3. Patients with indications for vac uum-assisted breast biopsy (VABB); 4. Preoperative Hospital Anxiety and Depression Scale (HADS) showed that the patient had anxiety and depression, that is, SAS score ≥7 points; 5. Patients who volunteered to participate in the trial with the consent of their family members and signed informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.妊娠(准备妊娠)期、哺乳期女性; 2.合并需要性激素治疗的疾病,如功能失调型子宫出血、闭经、多囊卵巢综合征、绝经期综合征、高泌乳素血症等; 3.合并恶性肿瘤的患者; 4.乳腺炎症性疾病患者; 5.对本项目试验药物成分有过敏者; 6.合并心、脑、肺、肾、肝和造血系统等的严重原发性疾病; 7.合并精神类疾病或智力障碍,存在听力或认知障碍的患者; 8.已经或准备接受其他方式治疗焦虑症的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant (preparing for pregnancy) or lactating women; 2. Concomitant diseases requiring sex hormone therapy, such as dysfunctional uterine bleeding, amenorrhea, polycystic ovary syndrome, menopausal syndrome, hyperprolactinemia, etc. 3. Patients with malignant tumors; 4.Patients with breast inflammatory disease; 5. Those who are allergic to the ingredients of the trial drugs; 6. Serious primary diseases of the heart, brain, lung, kidney, liver and hematopoietic system; 7. Patients with mental illness or intellectual disability, hearing or cognitive impairment; 8. Patients who have received or are prepared to receive other forms of treatment for anxiety. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
我们将患者随机平均分配进入三组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
We randomly and equally assigned patients to three groups. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲 |
|
Blinding: |
Single blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
将于试验结束后 6 个月内前将原始数据公开至临床试验公共管理平台 ResMan(www.medresman.org)上。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data will be made publicly available on the clinical trial management platform ResMan (www.medresman.org) within 6 months after the trial completion. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质表进行数据收集,待样本量全部完成后在进行电子数据录入。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Paper forms are used for data collection, and electronic data entry is performed once the sample size has been completed. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |